1. |
Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA, 2017, 317(13): 1338-1348.
|
2. |
van der Pol E, Böing AN, Harrison P, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev, 2012, 64(3): 676-705.
|
3. |
Nabet BY, Qiu Y, Shabason JE, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell, 2017, 170(2): 352-366.
|
4. |
Zhang H, Deng T, Liu R, et al. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat Commun, 2017, 8: 15016.
|
5. |
Ren J, He W, Zheng L, et al. From structures to functions: insights into exosomes as promising drug delivery vehicles. Biomater Sci, 2016, 4(6): 910-921.
|
6. |
Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 1983, 33(3): 967-978.
|
7. |
Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol, 1983, 97(2): 329-339.
|
8. |
Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem, 1987, 262(19): 9412-9420.
|
9. |
Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 2007, 9(6): 654-659.
|
10. |
Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol, 2008, 10(12): 1470-1476.
|
11. |
Gibbings DJ, Ciaudo C, Erhardt M, et al. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol, 2009, 11(9): 1143-1149.
|
12. |
Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun, 2011, 2: 180.
|
13. |
Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics, 2010, 73(10): 1907-1920.
|
14. |
Suchorska WM, Lach MS. The role of exosomes in tumor progression and metastasis (review). Oncol Rep, 2016, 35(3): 1237-1244.
|
15. |
Caby MP, Lankar D, Vincendeau-Scherrer C, et al. Exosomal-like vesicles are present in human blood plasma. Int Immunol, 2005, 17(7): 879-887.
|
16. |
Ogawa Y, Miura Y, Harazono A, et al. Proteomic analysis of two types of exosomes in human whole saliva. Biol Pharm Bull, 2011, 34(1): 13-23.
|
17. |
Admyre C, Johansson SM, Qazi KR, et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol, 2007, 179(3): 1969-1978.
|
18. |
Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta, 1985, 822(2): 203-218.
|
19. |
Park KH, Kim BJ, Kang J, et al. Ca2+ signaling tools acquired from prostasomes are required for progesterone-induced sperm motility. Sci Signal, 2011, 4(173): ra31.
|
20. |
Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A, 2004, 101(36): 13368-13373.
|
21. |
Vella LJ, Sharples RA, Lawson VA, et al. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol, 2007, 211(5): 582-590.
|
22. |
Masyuk AI, Huang BQ, Ward CJ, et al. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol, 2010, 299(4): G990-G999.
|
23. |
Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles, 2015, 4: 27066.
|
24. |
EL Andaloussi S, Mäger I, Breakefield XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov, 2013, 12(5): 347-357.
|
25. |
Hick AC, Delmarcelle AS, Bouquet M, et al. Reciprocal epithelial: endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation. Dev Biol, 2013, 381(1): 227-240.
|
26. |
Villacorte M, Delmarcelle AS, Lernoux M, et al. Thyroid follicle development requires Smad1/5- and endothelial cell-dependent basement membrane assembly. Development, 2016, 143(11): 1958-1970.
|
27. |
Degosserie J, Heymans C, Spourquet C, et al. Extracellular vesicles from endothelial progenitor cells promote thyroid follicle formation. J Extracell Vesicles, 2018, 7(1): 1487250.
|
28. |
Belge G, Rippe V, Meiboom M, et al. Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations. Cytogenet Cell Genet, 2001, 93(1-2): 48-51.
|
29. |
Rippe V, Dittberner L, Lorenz VN, et al. The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS One, 2010, 5(3): e9485.
|
30. |
Bullerdiek J, Flor I. Exosome-delivered microRNAs of " chromosome 19 microRNA cluster” as immunomodulators in pregnancy and tumorigenesis. Mol Cytogenet, 2012, 5(1): 27.
|
31. |
Vlasov P, Doi SQ, Sellitti DF. FRTL-5 rat thyroid cells release thyroglobulin sequestered in exosomes: a possible novel mechanism for thyroglobulin processing in the thyroid. J Thyroid Res, 2016, 2016: 9276402.
|
32. |
Bernecker C, Lenz L, Ostapczuk MS, et al. MicroRNAs miR-146a1, miR-155_2, and miR-200a1 are regulated in autoimmune thyroid diseases. Thyroid, 2012, 22(12): 1294-1295.
|
33. |
Yamada H, Itoh M, Hiratsuka I, et al. Circulating microRNAs in autoimmune thyroid diseases. Clin Endocrinol (Oxf), 2014, 81(2): 276-281.
|
34. |
Hiratsuka I, Yamada H, Munetsuna E, et al. Circulating microRNAs in Graves’ disease in relation to clinical activity. Thyroid, 2016, 26(10): 1431-1440.
|
35. |
Lee JC, Zhao JT, Gundara J, et al. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. J Surg Res, 2015, 196(1): 39-48.
|
36. |
Samsonov R, Burdakov V, Shtam T, et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol, 2016, 37(9): 12011-12021.
|
37. |
Boufraqech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer, 2014, 21(4): 517-531.
|
38. |
Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med, 2012, 18(6): 883-891.
|
39. |
Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature, 2015, 523(7559): 177-182.
|
40. |
Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol, 2015, 17(6): 816-826.
|
41. |
Vella LJ. The emerging role of exosomes in epithelial-mes- enchymal-transition in cancer. Front Oncol, 2014, 4: 361.
|
42. |
Greening DW, Gopal SK, Mathias RA, et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol, 2015, 40: 60-71.
|
43. |
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol, 2006, 7(2): 131-142.
|
44. |
Hardin H, Guo Z, Shan W, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol, 2014, 184(8): 2342-2354.
|
45. |
Pradella D, Naro C, Sette C, et al. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer, 2017, 16(1): 8.
|
46. |
Hardin H, Helein H, Meyer K, et al. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest, 2018, 98(9): 1133-1142.
|
47. |
Luo D, Zhan S, Xia W, et al. Proteomics study of serum exosomes from papillary thyroid cancer patients. Endocr Relat Cancer, 2018, 25(10): 879-891.
|
48. |
Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther, 2011, 19(10): 1769-1779.
|
49. |
Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res, 2015, 32(6): 2003-2014.
|
50. |
Tian Y, Li S, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials, 2014, 35(7): 2383-2390.
|
51. |
Gangadaran P, Li XJ, Kalimuthu SK, et al. New optical imaging reporter-labeled anaplastic thyroid cancer-derived extracellular vesicles as a platform for in vivo tumor targeting in a mouse model. Sci Rep, 2018, 8(1): 13509.
|
52. |
Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem, 2009, 284(49): 34211-34222.
|
53. |
Smyth TJ, Redzic JS, Graner MW, et al. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim Biophys Acta, 2014, 1838(11): 2954-2965.
|
54. |
Smyth T, Kullberg M, Malik N, et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release, 2015, 199: 145-155.
|
55. |
Zhu L, Li XJ, Kalimuthu S, et al. Natural killer cell (NK-92MI)-based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model. Front Immunol, 2017, 8: 816.
|
56. |
Shoae-Hassani A, Hamidieh AA, Behfar M, et al. NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells. J Immunother, 2017, 40(7): 265-276.
|
57. |
Zhang G, Liu R, Zhu X, et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol, 2013, 91(10): 615-624.
|
58. |
Fais S. NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology, 2013, 2(1): e22337.
|
59. |
Zhu L, Kalimuthu S, Gangadaran P, et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics, 2017, 7(10): 2732-2745.
|
60. |
Kalimuthu S, Gangadaran P, Li XJ, et al. In vivo therapeutic potential of mesenchymal stem cell-derived extracellular vesicles with optical imaging reporter in tumor mice model. Sci Rep, 2016, 6: 30418.
|
61. |
Jang SC, Gho YS. Could bioengineered exosome-mimetic nanovesicles be an efficient strategy for the delivery of chemo- therapeutics? Nanomedicine (Lond), 2014, 9(2): 177-180.
|
62. |
Wagner JA, Rosario M, Romee R, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest, 2017, 127(11): 4042-4058.
|
63. |
Zhu L, Kalimuthu S, Oh JM, et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials, 2019, 190-191: 38-50.
|
64. |
Zhu L, Gangadaran P, Kalimuthu S, et al. Novel alternatives to extracellular vesicle-based immunotherapy-exosome mimetics derived from natural killer cells. Artif Cells Nanomed Biotechnol, 2018, [Epub ahead of print].
|
65. |
Yang Z, Xie J, Zhu J, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. J Control Release, 2016, 243: 160-171.
|
66. |
黄胜林; 复旦大学医学院上海肿瘤研究所. exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. 2018-01-04. http://www.exorbase.org/.
|
67. |
Zhou CF, Ma J, Huang L, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene, 2018, [Epub ahead of print].
|
68. |
Yen EY, Miaw SC, Yu JS, et al. Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers. Am J Cancer Res, 2017, 7(11): 2199-2208.
|
69. |
韩茜, 张广, 孙辉. 超声引导下热消融治疗甲状腺微小乳头状癌研究进展. 中国普外基础与临床杂志, 2017, 24(9): 1156-1160.
|